Avantor (NYSE:AVTR) Price Target Cut to $23.00 by Analysts at Barclays

Avantor (NYSE:AVTR) had its price objective cut by Barclays from $26.00 to $23.00 in a research note issued to investors on Monday,Benzinga reports. They currently have an overweight rating on the stock.

Other analysts have also issued reports about the stock. Raymond James cut their target price on shares of Avantor from $29.00 to $26.00 and set an “outperform” rating for the company in a research report on Tuesday, January 21st. Robert W. Baird reduced their price objective on Avantor from $27.00 to $26.00 and set an “outperform” rating for the company in a research note on Monday, October 28th. Wells Fargo & Company lowered their target price on Avantor from $30.00 to $28.00 and set an “overweight” rating on the stock in a research report on Monday, October 28th. Finally, UBS Group restated a “neutral” rating and issued a $25.00 price target (down previously from $29.00) on shares of Avantor in a research report on Friday, January 17th. Three research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $26.15.

Avantor Stock Down 0.9 %

AVTR opened at $19.00 on Monday. The stock has a market capitalization of $12.93 billion, a price-to-earnings ratio of 41.30, a PEG ratio of 3.87 and a beta of 1.28. The firm has a 50 day moving average price of $21.73 and a 200-day moving average price of $23.47. Avantor has a twelve month low of $18.49 and a twelve month high of $28.00. The company has a quick ratio of 1.06, a current ratio of 1.54 and a debt-to-equity ratio of 0.84.

Avantor (NYSE:AVTR) last announced its earnings results on Wednesday, February 12th. The company reported $0.27 earnings per share for the quarter, beating analysts’ consensus estimates of $0.26 by $0.01. Avantor had a net margin of 4.54% and a return on equity of 12.24%. During the same quarter last year, the firm posted $0.22 earnings per share. Equities research analysts forecast that Avantor will post 0.98 earnings per share for the current year.

Institutional Trading of Avantor

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Public Employees Retirement System of Ohio grew its position in shares of Avantor by 34.1% during the third quarter. Public Employees Retirement System of Ohio now owns 346,822 shares of the company’s stock valued at $8,972,000 after purchasing an additional 88,205 shares in the last quarter. Perpetual Ltd boosted its stake in Avantor by 38.7% during the fourth quarter. Perpetual Ltd now owns 1,766,882 shares of the company’s stock valued at $37,228,000 after buying an additional 493,408 shares during the last quarter. New York State Teachers Retirement System purchased a new position in Avantor during the 3rd quarter valued at approximately $8,473,000. Everence Capital Management Inc. bought a new stake in Avantor in the 4th quarter worth approximately $555,000. Finally, Teachers Retirement System of The State of Kentucky raised its holdings in shares of Avantor by 45.8% during the 3rd quarter. Teachers Retirement System of The State of Kentucky now owns 723,178 shares of the company’s stock worth $18,708,000 after acquiring an additional 227,200 shares in the last quarter. 95.08% of the stock is currently owned by institutional investors.

About Avantor

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.